publication venue for
- Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency. 10:1995168. 2021
- Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers. 10:1885778. 2021
- Tumor-intrinsic determinants of immunogenic cell death modalities. 10:1893466. 2021
- Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?. 8:e1581528-e1581528. 2019
- Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. 8:e1512329. 2019
- Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. 7:e1503032-e1503032. 2018
- Transforming the prostatic tumor microenvironment with oncolytic virotherapy. 7:e1445459-e1445459. 2018
- Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages. 7:e1423171-e1423171. 2018
- Consensus guidelines for the detection of immunogenic cell death. 3:e955691-e955691. 2014
- Rewiring cancer cell death to enhance oncolytic viro-immunotherapy. 2:e27138-e27138. 2013
- Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+T-cell responses to anticancer vaccines. 2:e26013-e26013. 2013
- Myeloid-derived suppressor cells, age and cancer. 2:e24754-e24754. 2013
- Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. 1:419-431. 2012